

Registered number: 14516549

STELIS BIOPHARMA UK PRIVATE LIMITED

UNAUDITED

DIRECTORS' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

WEDNESDAY



AE12G08Z

A03

23/04/2025

#213

COMPANIES HOUSE

STELIS BIOPHARMA UK PRIVATE LIMITED

COMPANY INFORMATION

Directors	Pudhucode Radhakrishnan Kannan Onesource Specialty Pharma Limited
------------------	--

Registered number	14516549
--------------------------	----------

Registered office	Unit 4 Metro Centre Tolpits Lane Watford Hertfordshire WD18 9SS
--------------------------	---

STELIS BIOPHARMA UK PRIVATE LIMITED

CONTENTS

	Page
Directors' report	1
Profit and loss account	2
Balance sheet	3
Notes to the financial statements	4

STELIS BIOPHARMA UK PRIVATE LIMITED

**DIRECTORS' REPORT
FOR THE YEAR ENDED 31 MARCH 2025**

The directors present their report and the financial statements for the year ended 31 March 2025.

Directors


The directors who served during the year were:

Pudhucode Radhakrishnan Kannan
Onesource Specialty Pharma Limited

Small companies note

In preparing this report, the directors have taken advantage of the small companies exemptions provided by section 415A of the Companies Act 2006.

This report was approved by the board and signed on its behalf.



.....
Pudhucode Radhakrishnan Kannan
Director

Date: 17/4/25

STELIS BIOPHARMA UK PRIVATE LIMITED

**PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 31 MARCH 2025**

The Company has not traded during the year or the preceding financial year. During these periods, the Company received no income and incurred no expenditure and therefore made neither profit or loss.

STELIS BIOPHARMA UK PRIVATE LIMITED
REGISTERED NUMBER: 14516549

BALANCE SHEET
AS AT 31 MARCH 2025

	Note	2025 £	2024 £
Current assets			
Debtors: amounts falling due within one year	2	100	100
		<u>100</u>	<u>100</u>
Total assets less current liabilities		100	100
Net assets		<u>100</u>	<u>100</u>
Capital and reserves			
Called up share capital		100	100
Shareholders' funds		<u>100</u>	<u>100</u>


For the year ended 31 March 2025 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:



Pudhucode Radhakrishnan Kannan
Director

Date: 17/4/25

The notes on page 4 form part of these financial statements.

STELIS BIOPHARMA UK PRIVATE LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

1. Accounting policies**1.1 Basis of preparation of financial statements**

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

2. Debtors

	2025 £	2024 £
Other debtors	100	100
	<u>100</u>	<u>100</u>